Electroencephalography Devices Market Size to Reach USD 4.17 Bn by 2035

According to analysts at Vantage Market Research, the Global Electroencephalography Devices Market size is worth USD 1.43 Billion in 2024 and is projected to reach USD 4.17 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 10.2% from 2025 to 2035. Key trends include AI integration, increased research applications, telemedicine growth, focus on brain-computer interfaces, and home monitoring solutions.

Market Overview

The Electroencephalography devices market is driven by the growing incidence of neurological disorders, the increasing need for non-invasive diagnostic methods, and advancements in EEG technology. The increasing elderly population and heightened awareness about the importance of early detection of neurological conditions are expected to drive market growth. Additionally, conditions such as epilepsy, Alzheimer’s disease, Parkinson’s disease, and sleep disorders are becoming more prevalent due to factors like an aging population and lifestyle changes. For instance, as people age, the likelihood of developing neurological conditions increases, particularly Alzheimer’s disease and Parkinson’s.

High-end EEG devices, particularly those with more sophisticated features like high-channel configurations (32 or more channels) and integrated neuroimaging capabilities (such as combining EEG with functional MRI or MEG), can be prohibitively expensive. The expense of these systems is increased by the need for specialist equipment and the frequently difficult setup and maintenance procedures. The exorbitant cost of these sophisticated EEG equipment prevents their widespread use by healthcare providers, especially in underdeveloped nations.

Bath and Bristol Universities Receive USD 1.5 Million to Advance Fastball EEG Test for Early Dementia Detection

• In July 2023, a major funding of USD 1.5 million was awarded to the universities of Bath and Bristol to support the development of the Fastball EEG test. This user-friendly test is designed to aid in the early detection of dementia and Alzheimer's disease, benefiting both patients and their families

Key Takeaways from the Report

• In 2024, North America dominated the market with 36.2% market share. Market is driven by the rising prevalence of neurological disorders and increased insurance coverage
• Based on the Product, the 32-channel EEG category accounted for significant market share of 28.1%. The segment is driven by the device's improved diagnostic accuracy and higher spatial resolution
• Based on the Type, the Standalone Devices category accounted for significant market share of 71.5%. Standalone EEG devices are ideal for usage in hospitals, clinics, and research facilities
• By Application, Disease Diagnosis dominated the market with market share of 30.5%. EEG devices are essential for diagnosing neurological disorders such as epilepsy, Alzheimer’s, and Parkinson’s disease
• By End-Use, Hospitals dominated the market with significant market share of 66.5%. The segment is driven by the rising incidence of neurological disorders and the demand for advanced healthcare services

Top Companies

• Medtronic
• Nihon Kohden America Inc.
• Natus Medical Inc.
• Brain Products GmbH
• Neurosoft
• Compumedics Ltd.
• Electrical Geodesics Inc.
• ANT Neuro
• EBNeuro
• Magstim EGI
• Emotiv
• Lifelines Neuro
• Mitsar
• Micromed
• Cadwell Laboratories Inc.

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Gate and Beacon Collaborate to Use EEG Biomarkers in Phase II Trial for Major Depressive Disorder

• In January 2024, Beacon and Gate began a collaboration to integrate EEG biomarkers into Gate's Phase II trial for Major Depressive Disorder (MDD). This trial, starting in mid-2024, will incorporate Beacon's Dreem 3S headband for exploratory EEG and sleep analysis in participants. The primary goal of the Phase II trial is to further the understanding and treatment options for MDD, focusing on Gate's investigational drug, zelquistine